{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273329","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.113940+00:00","generated_at":"2026-05-16T22:27:17.322586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive","bullets":["Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).","CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.","CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.","CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.","SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273329","json":"https://secwatch.observer/filing/0001193125-25-273329.json","markdown":"https://secwatch.observer/filing/0001193125-25-273329.md","text":"https://secwatch.observer/filing/0001193125-25-273329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/0001193125-25-273329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312525273329/crsp-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:27:17.322586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}